However, one needs to be cognizant that poor dose regimen design can result in suboptimal efficacy, on-therapy resistance development, and resistance selection that may harm the activity of all β-lactam-β-lactamase inhibitor combinations.
Additional barriers to adherence include psychiatric disorders, such as depression or substance use, uncertainty about the effectiveness of treatment and the consequences of poor adherence, regimen complexity, and treatment side effects.
It should be possible to overcome this limitation by using laboratory-reared animals of the same age, but reared under different conditions (e.g. rich or poor food regimen) and therefore differing in size.
There are multiple causes of poor adherence: regimen complexity, side effects etc. Aim: to analyze ART adherence, risk factors for poor adherence and their impact on the outcome.
We analyzed some possible risk factors for poor adherence: gender, regimen rank and complexity.
Although positive results are frequently observed in those with an HLA-matched sibling donor, use of unrelated donors has been complicated by poor engraftment, excessive regimen-related toxicity, and graft-versus-host disease (GVHD).
As well as the risk of these possible adverse effects not all patients respond to these treatments and non-adherence to treatment is common due to issues such as complex treatment regimens, poor inhalation technique and delayed results [10] thus there is an unmet medical need for complementary therapies for asthma.
This achievement contrasts with results in sub-Saharan countries where, each year, nearly 400,000 infants continue to acquire HIV infection through perinatal HIV transmission, a consequence of limited drug regimens, poor access to care and poor service delivery [4].
Results from uni- and multivariable logistic regression analyses for both eras are shown in Figure 4. Virological failures were independently associated with the number of previous failed regimens, poor adherence, and lack of having ever reached complete viral suppression.
